marquis ponazuril
Each barrel of syringes from MARQUIScontains sufficient paste for treating 1 (1) 1,200 lbs (544 kilograms) horse, for 7 (7) days with a dose that is 5 mg/kg (2.27 mg/lb) body weight, or to treat a 1,200 pounds (544 kilogram) horse using one dose of loading 15 mg/kg (6.81 mg/lb) body weight, and for the next four days at a dose rate five mg/kg (2.27 mg/lb) body weight. The plunger is equip with a dose rings that are calibrate for a dosage that is 5 mg/kg (2.27 mg/lb) body weight, and is the weight of horses ranges of 600- 1,200 pounds (272 up to 544 kilograms). The barrel of syringes is pack with the plunger. Syringe barrels are pack in four parts with four plungers that can be reuse and as single syringes with a reused plunger. marquis ponazuril
Ataxia is the most common neurologic disorder were report to be acutely worsen in the initial treatment phase. In certain horses, the deterioration of neurologic problems was temporary. ( See Post Approval Experience Section ).Clinicians must be aware that the elimination of parasites by ponazuril might not be enough to completely eliminate the clinical signs that are attribute to the natural course in the course of disease. The outcome of animals who are treat for EPM could be contingent on the severity of the disease and the duration of the illness at the time of treatment.
The safety of using MARQUISin horses that are use to breed, whether during pregnancy or lactating mares has not been analyzed. The safety of MARQUIS in conjunction with other treatments in horses hasn’t been evaluated.
Based on MARQUISFOI Summaries. Study 141-188 Bayer Corporation.
Trademarks
MARQUIS(r)is an trademark register by Boehringer Ingelheim Animal Health USA Inc. (c)2021 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.
IMPORTANT SAFETY INFORMATION
The use of MARQUISin horses to breed purposes, during lactating or during pregnancy is not yet assess. In studies of animal safety loose feces and sporadic inappetence, weight loss and moderate edema of the epithelium of the uterus were noted. Only for use on animals. It is not intended for use by humans. Be sure to keep it out of the reach of children.
IMPORTANT SAFETY INFORMATION
The safety of using MARQUISin horses for breeding purposes the lactation process or in pregnant mares is not yet evaluated. In safety studies on animals loose feces, occasional inappetence, weight loss and moderate edema within the epithelium of the uterine lining were observed. This product is intended for use only in animals. Do not use for human consumption. Keep away from your reach
marquis ponazuril
Ponazurilis is an anticoccidial (antiprotozoal) substance that acts against a variety of genera belonging to the Apicomplexa phylum. Apicomplexa.
MARQUIS(r)(15% w/w ponazuril)Antiprotozoal Oral Paste is supply in a ready-to-use syringe containing 127 grams of paste. The gram has 150 milligrams of ponazuril(15 percent in w/w). Marquis is intend to be give in the form of an oral paste.
Chemical nomenclature and structure: Ponazuril1,3,5-Triazine-2,4,6(1H,3H,5H)-trione,1-methyl-3-[3-methyl-4-[4-[(trifluoromethyl)sulfonyl] phenoxy]phenyl]-(9Cl)
Clinical Pharmacology:
The ponazuril’s activity has been observe in a variety of Apicomplexans1-6. Lindsay, Dubey and Kennedy7 demonstrated that the amount of ponazuril needed to eliminate Sarcocystis neurons in vitro ranged from 0.1 or 1.0 mg/mL. Furr and Kennedy8 assessed the pharmacokinetics the ponazurilin syringe and CSF in healthy horses. They treated daily with 5 mg/kg for 28 days. The time to reach peak the serum level (Tmax) is 18.20 (+-5.9) days, and the highest serum concentration (Cmax) is 5.59 (+-0.92) mg/mL. The final elimination half-life of serum (calculated by using the Day 28 to 42 results) measured 4.50 (+-0.57) days. Within CSF, Tmax was 15.40 (+-7.9) days, and Cmax reached 0.21 (+-0.072) mg/mL.
A pharmacokinetic study was carry out on eight horses in order to determine blood and cerebrospinal fluid (CSF) amounts of ponazuril following one dosage of five mg/kg weight. The estimate parameters were use to construct the time-dependent concentration profiles of the ponazurilin in blood and CSF.
The model’s results were use to determine the amount of the dosage need to achieve stable serum levels and CSF levels following the initial dose. The most appropriate dose for loading, determine base on the ratio of accumulation (i.e. the increase in the concentration of serum drugs once stable state conditions are reach) is 15 mg/kg (6.81 mg/lb) body weight. This dosage represents the estimated range of accumulation ratios ranging from 2.3 between 2.3 and 3.3. Thus, a three-fold loading dose (3*5 mg/kg) was select, leading to achievement of steady state blood levels in horses after one or two days of ponazuriladministration.
marquis ponazuril
Before the treatment process, EPM should be distinguish from other conditions that can cause ataxia in horses. Lameness or injuries can make it difficult to evaluate the animal suffering from EPM. The majority of cases ataxia caused by EPM is asymmetrical, and it affects the hind legs.
The neurologic impairments, most notably ataxia are know to be acutely worsen in the initial treatment phase. In some horses, the deterioration of neurologic problems was only temporary. (See Post Approval Experience Section).
Clinicians must recognize that the removal of the parasite with ponazuril may not be enough to completely eliminate the clinical symptoms attributed to the natural course in the course of disease. The outcome of animals that are treat for EPM could be contingent on the severity of the disease as well as the length of the illness before treatment.
The use of MARQUISin horses that are use to breed, in the lactation process, or even in lactating mares, hasn’t been assess. The safety of MARQUIS in conjunction with other treatments in horses hasn’t been analyze.
Adverse Reactions:
In field studies, 8 horses were observe to have observations that were unusual throughout the day. Two horses showed blisters on their noses and mouth at one time during the field study. Three animals had a skin rash or hives that lasted at least 18 consecutive days, an animal suffered from loose stool during the duration of treatment, and one suffered from mild colic one day, and one animal suffered a seizure when taking medication. The connection between the reactions with treatment was not determine.
marquis ponazuril
The following adverse events that occur in horses are determine by the adverse drug experience report after approval. The majority of adverse events aren’t report to the FDA/CVM. It’s not always possible to accurately estimate the adverse events’ frequency as well as establish a causal connection to exposure to the product by with these information. These adverse incidents have been document:
The neurologic impairments, most notably ataxia, were report to be acutely worsen in the first few days of treatment. While the outcome was not always document for all horses, it was report that in a few of them the increase in neurologic impairments was only temporary.
To notify of suspected adverse drug reactions For technical assistance or to request an exact version of the Safety Data Sheet (SDS) Contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-451.
For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.
Animal Safety Summary:
MARQUISwas given in 24 mature animals (12 males, and females) as part of a safety study. Three groups of horses received either 0 30, 10, and 30 mg/kg (water as a control 2X and 6X for 5-mg/kg [2.27 mg/lb] dosage). Horses were dose immediately following their having a meal. A portion from each of the groups was give treatment for 28 days, and the other for 56 days. This was follow by necropsy after the end of treatment. There were many cases of loose feces among all the animals studied regardless of treatment. There was also occasional inappetence, and a horse with 10% mg/kg (2X) dropped weight in the test. Feces that were loose were related to treatment. Histopathological examination reveal moderate edema within the epithelium of the uterine lining in thr
Dosage:
Take MARQUISat in a dose of mg/kg (6.81 mg/lb) body weight to load the first dose alone.
Day 1: Give an initial dose 15 mg/kg (three times the dose for maintenance) every day via mouth.
Day 2 to 28: Take the dose for maintenance of 5 mg/kg twice every day by taking a mouthful.
Assembling
Before syringe administration, the barrel and plunger need to be assemble. Check that the plunger is clean dry.
The cap at the end must be attache to the barrel of the syringe when inserting the plunger
marquis ponazuril
The horse is administer MARQUIS:
Be aware that the paste syringe is a multi-dose system. Make sure that the right dose is dispense at each time. In the initial dose take steps 3 through 6 three times. After that, follow steps 7 and 8.
Take off the cap at the end and gently press the plunger. Until the paste can be visible at the top of the barrel. Reattach end cap to the end of the paste syringe
Determine the weight of your horse, and ensure that its mouth is not contaminate with feed.
To gauge dose, the dosage rings, barrel collars and ring collars must be in a completely flush. Place the plunger in your hand and turn the dose ring by rotating another hand, Adjusting it to the capacity of your horse.
Remove cap at the tip of barrel.
The paste dose that you have chosen is to be apply on the back and on top of the tongue of the horse. Introduce the tip of the syringe to the sides of the mouth of the horse in the gap between his teeth that are in front (incisor) and the rear (molar) teeth. Place the paste onto the tongue of the horse by pressing it with the plunger to as much that the ring of dose will allow. Then, remove the tip of the syringe from the horse’s mouth.